University of Minnesota School of Medicine, Department of Obstetrics, Gynecology and Women's Health, 420 Delaware St. SE, MMC 395, Minneapolis, MN 55455, USA.
University of Minnesota School of Medicine, 420 Delaware St. SE, MMC 395, Minneapolis, MN 55455, USA.
Gynecol Oncol. 2019 Aug;154(2):276-279. doi: 10.1016/j.ygyno.2019.05.028. Epub 2019 Jun 3.
This study aims to evaluate whether re-excision or adjuvant radiation for stage I vulvar squamous cell carcinoma (SCC) with either a close or positive surgical margin improves recurrence-free survival.
Patients with pathologically confirmed FIGO stage I vulvar SCC who underwent primary surgical management between January 1, 1995 and September 30, 2017 and had positive or close (<8 mm) surgical margins were included. Kaplan-Meier curves were generated and compared using the log-rank test.
Of 150 patients with stage I vulvar SCC, 47 (31.3%) had positive or close margins. Median follow-up time was 25 months (IQR 13-59 months). Twenty-one (44.6%) patients received additional treatment with re-excision (n = 17) or vulvar radiation (n = 4); 26 (55.3%) patients received no additional therapy. Patients with positive margins were more likely to receive additional therapy compared to patients with close margins (80% vs 35.1%, p = 0.03). The 2-year recurrence rates were similar between the no further therapy and the re-excision/vulvar radiation groups (11.5% vs 4.8%, p = 0.62). Local recurrence-free survival (RFS) and overall survival (OS) were similar between patients who received re-excision/vulvar radiation and patients who received no further therapy (p = 0.10 and p = 0.16, respectively). Subgroup analysis of the 37 patients with close margins demonstrated no difference in RFS or OS when patients received re-excision or adjuvant vulvar radiation compared to no additional therapy (p = 0.74 and p = 0.82, respectively).
In our study, any additional treatment following primary surgical resection did not improve RFS or OS in stage IA and IB vulvar SCC. Larger studies are warranted in order to definitively determine the role of re-excision and adjuvant radiation in early stage disease.
本研究旨在评估对于切缘阳性或近切缘(<8mm)的Ⅰ期外阴鳞癌(SCC)患者行再次切除术或辅助放疗是否能改善无复发生存率。
本研究纳入了 1995 年 1 月 1 日至 2017 年 9 月 30 日期间行初次手术治疗且术后病理证实为Ⅰ期外阴 SCC 且切缘阳性或近切缘(<8mm)的患者。采用 Kaplan-Meier 曲线进行生存分析,并采用对数秩检验进行比较。
在 150 例Ⅰ期外阴 SCC 患者中,47 例(31.3%)存在切缘阳性或近切缘。中位随访时间为 25 个月(IQR:13-59 个月)。21 例(44.6%)患者接受了进一步治疗,包括再次切除术(n=17)或外阴放疗(n=4);26 例(55.3%)患者未接受进一步治疗。与切缘近切缘患者相比,切缘阳性患者更有可能接受进一步治疗(80% vs 35.1%,p=0.03)。未进一步治疗组与再次切除术/外阴放疗组的 2 年复发率相似(11.5% vs 4.8%,p=0.62)。再次切除术/外阴放疗组与未进一步治疗组的局部无复发生存率(RFS)和总生存率(OS)相似(p=0.10 和 p=0.16)。对于 37 例切缘近切缘的患者进行亚组分析显示,与未进一步治疗相比,接受再次切除术或辅助外阴放疗的患者的 RFS 或 OS 无差异(p=0.74 和 p=0.82)。
在本研究中,对于ⅠA 和ⅠB 期外阴 SCC 患者,初次手术切除后进行任何额外治疗均不能改善 RFS 或 OS。需要进一步开展更大规模的研究以明确再次切除术和辅助放疗在早期疾病中的作用。